Developer docs
API playgroundTry for free, no card

Search company profiles

Vaxxas

Full company profile

uuid0000cr6

Namestring
Vaxxas
Legal namestring
Vaxxas Pty Ltd
Websiteurl
vaxxas.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Vaxxas Pty Ltd is an Australian clinical-stage biotechnology company founded in 2011 as a spin-out from the University of Queensland, headquartered in Brisbane with US operations in Cambridge, Massachusetts. The company develops and is commercializing the High-Density Microarray Patch (HD-MAP), a needle-free vaccine delivery platform consisting of a patch with thousands of vaccine-coated microprojections (~0.25mm) integrated into a single-use applicator that delivers vaccine directly to immune cells below the skin surface. The platform has been validated in 5+ Phase I clinical trials covering COVID-19 (HexaPro), seasonal influenza (IIV4), pre-pandemic H7N9 influenza, measles and rubella, and typhoid, with over 750 participants dosed, and is being extended to RSV, mRNA and DNA-based vaccines. Key technical differentiators include dry-coating technology enabling thermostability at 40°C for up to 12 months (eliminating cold-chain logistics), dose-sparing potential, and a path to self-administration.

Vaxxas pursues a hybrid business model spanning four commercial segments: (1) licensing the HD-MAP platform to global pharmaceutical companies — Merck/MSD holds exclusive rights to one undisclosed vaccine candidate plus options for two additional candidates under a collaboration originating in 2012; (2) government and global health agency contracting for pandemic preparedness and low-and-middle-income country vaccine access, with awards from BARDA (US$22M in 2020 plus US$2M BARDA Prize in 2025), CEPI (US$4.8M mRNA program), Wellcome (US$3.67M typhoid) and Gates Foundation (measles/rubella Phase I); (3) in-licensing and self-commercializing proprietary vaccine candidates including RSV from NIH and HexaPro from University of Texas; and (4) a new European market entry via consortium with SK bioscience and IDT Biologika, awarded a Phase 1 EU HaDEA tender in February 2026 with up to A$250M available across three phases. All HD-MAP products remain under clinical investigation and none are approved for sale.

The company is preparing for commercial scale, having opened a 5,500 sqm purpose-built Brisbane biomedical facility in June 2023, secured a TGA manufacturing licence in December 2025 enabling up to 300 million patches per year, raised approximately A$90M in equity and debt in August 2025, and appointed former Merck Global Vaccines President David Peacock as CEO in January 2026 to lead commercialization. Backers include OneVentures (lead investor since founding), UniQuest, Brandon Capital, HealthCare Ventures, and non-dilutive funders including BARDA, the EU, CEPI, Gates and Wellcome; total disclosed funding identified in the data exceeds A$250M.

Short descriptiontext

Vaxxas is a clinical-stage Australian biotechnology company developing the HD-MAP, a needle-free microarray patch platform for delivering vaccines to immune cells beneath the skin. It serves global pharmaceutical partners, government pandemic-preparedness agencies, and global-health organizations across programs in COVID-19, influenza, RSV, measles/rubella and typhoid.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBrisbane, Australia
HQ citystring
Brisbane
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
needle-free vaccination, microarray patch delivery, vaccine delivery platform, biopharmaceutical technology, pharmaceutical licensing
Industry1 code
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Vaccine Delivery Technology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing
TypeLicensing Royalties
Description

Licensing the proprietary HD-MAP platform technology to global pharmaceutical companies for use with their vaccine candidates. Merck/MSD has exclusive rights for one vaccine candidate and options for two additional vaccines.

vaxxas.com
2Grant Funding and Government Contracts
TypeSubscription Recurring
Description

Funding from government agencies (BARDA, EU HaDEA) and global charitable foundations (Gates Foundation, Wellcome, CEPI) to advance clinical programs and manufacturing capabilities.

vaxxas.com
3Direct Vaccine Product Commercialization
TypeHardware Sales
Description

Commercializing proprietary and in-licensed vaccine candidates (COVID-19 HexaPro, RSV, pandemic influenza, typhoid, measles/rubella) through late-stage clinical trials to market entry.

vaxxas.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vaxxas develops and commercializes the proprietary HD-MAP (High-Density Microarray Patch) platform, a needle-free vaccine delivery technology consisting of a patch with thousands of vaccine-coated microprojections (~0.25mm) integrated with a single-use applicator that delivers vaccine to immune cells beneath the skin. The company applies this platform across multiple investigational vaccine programs including COVID-19, seasonal and pre-pandemic influenza, measles and rubella, RSV, and typhoid, while licensing the technology to global pharmaceutical partners such as Merck/MSD for use with their vaccine candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • COVID-19 pandemic could have been reduced by 150 days with MAP technology deployment, potentially preventing 16.3 million cases and 200,000 deaths in US alone
+3 more records
Product overview1 text field

Vaxxas is commercializing the HD-MAP (High-Density Microarray Patch) as a universal needle-free vaccine delivery platform. The core HD-MAP technology consists of a small patch with thousands of microscopic vaccine-coated projections integrated into a single-use applicator device that delivers vaccine to immune cells just below the skin surface. Vaxxas applies this platform across multiple vaccine programs including COVID-19 (HexaPro), seasonal influenza (IIV4), pre-pandemic influenza (H7N9), measles and rubella, RSV, and typhoid, all delivered as investigational patches. The platform is designed to enable dose-sparing, thermostability (stable at up to 40°C), potential self-administration, and enhanced immunogenicity compared to needle-and-syringe delivery. The company is also advancing mRNA and DNA-based vaccine delivery via HD-MAP. Vaxxas operates under four commercial segments: pandemic response, HD-MAP licensing to pharmaceutical companies (including Merck/MSD), global health vaccine extension, and in-licensing vaccines for its own commercialization.

Product and service9 records
1HD-MAP (High-Density Microarray Patch) Platform
CategoryVaccine Delivery Platform
2COVID-19 Vaccine Patch (HexaPro)
CategoryInvestigational Vaccine Program
3Seasonal Influenza Vaccine Patch (IIV4)
CategoryInvestigational Vaccine Program
4Pre-Pandemic Influenza Vaccine Patch (H7N9)
CategoryInvestigational Vaccine Program
5Measles and Rubella Vaccine Patch
CategoryInvestigational Vaccine Program
6RSV Vaccine Patch
CategoryInvestigational Vaccine Program
7Typhoid Vaccine Patch
CategoryInvestigational Vaccine Program
8mRNA Vaccine Delivery via HD-MAP
CategoryInvestigational Vaccine Program
9EU Next-Generation Influenza Vaccine Program
CategoryInvestigational Vaccine Program
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Part of global consortium awarded €12.9M Phase 1 tender by EU HaDEA for next-generation influenza vaccines. SK bioscience supplies vaccine antigens (SKYCellflu) and leads European collaboration. Consortium can access up to A$250M across phases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Part of EU HaDEA consortium for influenza vaccine development. IDT Biologika (owned by SK bioscience) leads the consortium submission and provides CDMO capabilities. Over 100 years of vaccine development and manufacturing experience.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-10-28
Description

Three-year partnership to support clinical trials using HD-MAP technology with ObvioGo digital trial platform. Decentralized trial capabilities to extend access.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-22
Description

Partnering on US$4.8M/AU$7.2M program for needle-free thermostable mRNA vaccines. Joint development to eliminate frozen storage requirements for mRNA vaccines.

5US National Institutes of Health (NIH)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-25
Description

Licensed next-generation RSV vaccine candidate from NIH for worldwide development using HD-MAP platform.

vaxxas.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2022-05-31
Description

Collaborative study with University of Sydney Institute for Infectious Diseases assessing usability and acceptability of HD-MAP applicator in clinical settings. Published in Journal of Human Vaccines and Immunotherapeutics.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-23
Description

Exclusively licensed HexaPro spike glycoprotein from UT Austin for use on needle-free vaccine patches. COVID-19 vaccine candidate completed Phase I trials.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Previous collaboration on simulation of vaccine administration using HD-MAP with children in Low and Middle-Income Countries. WHO has acknowledged MAP technology in pandemic preparedness plans.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2020-05-28
Description

Alliance to develop industrial-scale aseptic processing line for vaccine products based on HD-MAP technology. Supports manufacturing scale-up requirements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collaboration and license agreement where Merck has exclusive rights to utilize Vaxxas' HD-MAP platform for an undisclosed vaccine candidate from Merck's pipeline, with options for two additional vaccines. One of Vaxxas' foundational commercial partnerships.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2011-01-01
Description

Core technology (HD-MAP) initially developed at UQ's Australian Institute for Bioengineering and Nanotechnology. Commercialized as startup in 2011 through UniQuest.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Micron Biomedical is the most direct competitor, developing dissolvable microneedle array patches for vaccines and therapeutics. Both target needle-free vaccine delivery with similar microarray patch architectures and are pursuing global health and pandemic preparedness use cases, often competing for the same Gates Foundation, CEPI, and government grant funding.

2Vaxess Technologies
TypeDirect peer
Description

Vaxess is developing a sustained-release microarray patch for vaccine delivery using silk fibroin-based microneedles. Closely comparable technology platform and target use cases (influenza, pandemic preparedness, global health), positioned as a direct peer for both commercial licensing deals and non-dilutive funding opportunities.

TypeDirect peer
Description

PharmaJet develops needle-free jet injector devices for vaccine administration (different mechanism but same needle-free vaccine delivery goal). Competes for the same global health and pandemic preparedness customers (WHO, Gates, CEPI) and targets similar market positioning around dose-sparing and cold-chain reduction.

TypeEmerging player
Description

Corium develops transdermal drug and vaccine delivery technologies including microarray and patch systems. Comparable technology overlap in the transdermal/microneedle delivery category, though Corium's primary focus has historically been CNS and small molecule drug delivery rather than vaccines.

TypeBroad incumbent
Description

BD is a global medical device incumbent with established injectable drug delivery and emerging microneedle programs, plus deep relationships with pharmaceutical partners and global health agencies. Represents both a potential partner and a formidable incumbent competitor as microarray patch commercialization scales.

TypeBroad incumbent
Description

Merck is Vaxxas' largest licensing partner for HD-MAP and the world's leading vaccine manufacturer (>$10B vaccine business). Both a critical partner and an emerging peer given Merck's option to license HD-MAP across multiple vaccine candidates plus potential internal patch development efforts.

TypeBroad incumbent
Description

CSL Seqirus is a global influenza vaccine leader and an Australia-based peer comparable to Vaxxas on geography and target indication (seasonal and pandemic influenza). Relevant given Tom Lake (Vaxxas CBO) has deep CSL/Seqirus domain expertise and Vaxxas' H7N9 and seasonal flu programs target Seqirus's core market.

8Sanofi Pasteur
TypeBroad incumbent
Description

Sanofi Pasteur is one of the world's largest vaccine manufacturers with deep pandemic preparedness capabilities and prior collaboration with Merck in vaccine manufacturing (Tom Lake's experience). Represents a plausible next licensing partner for HD-MAP and a strategic acquirer given platform synergies.

TypeBroad incumbent
Description

GSK is a top-3 global vaccine manufacturer with strong portfolio overlap (influenza, measles/rubella, RSV, typhoid) where Vaxxas is developing HD-MAP programs. Comparable given Angus Forster (Vaxxas CTO/COO) and Tom Lake (Vaxxas CBO) both came from GSK. Plausible strategic partner or acquirer.

10Emergex Vaccines
TypeEmerging player
Description

Emergex is a clinical-stage biotech developing T-cell vaccines using microneedle patch delivery for infectious diseases including pandemic preparedness indications. Comparable stage, technology focus (microneedle delivery), and target indications (pandemic influenza, dengue) make it a relevant emerging peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaxxas

Vaccine Delivery Technologyvaxxas.com

Vaxxas is a clinical-stage Australian biotechnology company developing the HD-MAP, a needle-free microarray patch platform for delivering vaccines to immune cells beneath the skin. It serves global pharmaceutical partners, government pandemic-preparedness agencies, and global-health organizations across programs in COVID-19, influenza, RSV, measles/rubella and typhoid.

What Vaxxas does

Vaxxas Pty Ltd is an Australian clinical-stage biotechnology company founded in 2011 as a spin-out from the University of Queensland, headquartered in Brisbane with US operations in Cambridge, Massachusetts. The company develops and is commercializing the High-Density Microarray Patch (HD-MAP), a needle-free vaccine delivery platform consisting of a patch with thousands of vaccine-coated microprojections (~0.25mm) integrated into a single-use applicator that delivers vaccine directly to immune cells below the skin surface. The platform has been validated in 5+ Phase I clinical trials covering COVID-19 (HexaPro), seasonal influenza (IIV4), pre-pandemic H7N9 influenza, measles and rubella, and typhoid, with over 750 participants dosed, and is being extended to RSV, mRNA and DNA-based vaccines. Key technical differentiators include dry-coating technology enabling thermostability at 40°C for up to 12 months (eliminating cold-chain logistics), dose-sparing potential, and a path to self-administration.

Vaxxas pursues a hybrid business model spanning four commercial segments: (1) licensing the HD-MAP platform to global pharmaceutical companies — Merck/MSD holds exclusive rights to one undisclosed vaccine candidate plus options for two additional candidates under a collaboration originating in 2012; (2) government and global health agency contracting for pandemic preparedness and low-and-middle-income country vaccine access, with awards from BARDA (US$22M in 2020 plus US$2M BARDA Prize in 2025), CEPI (US$4.8M mRNA program), Wellcome (US$3.67M typhoid) and Gates Foundation (measles/rubella Phase I); (3) in-licensing and self-commercializing proprietary vaccine candidates including RSV from NIH and HexaPro from University of Texas; and (4) a new European market entry via consortium with SK bioscience and IDT Biologika, awarded a Phase 1 EU HaDEA tender in February 2026 with up to A$250M available across three phases. All HD-MAP products remain under clinical investigation and none are approved for sale.

The company is preparing for commercial scale, having opened a 5,500 sqm purpose-built Brisbane biomedical facility in June 2023, secured a TGA manufacturing licence in December 2025 enabling up to 300 million patches per year, raised approximately A$90M in equity and debt in August 2025, and appointed former Merck Global Vaccines President David Peacock as CEO in January 2026 to lead commercialization. Backers include OneVentures (lead investor since founding), UniQuest, Brandon Capital, HealthCare Ventures, and non-dilutive funders including BARDA, the EU, CEPI, Gates and Wellcome; total disclosed funding identified in the data exceeds A$250M.

Vaxxas firmographics

Firmographics
Name
Vaxxas
Legal name
Vaxxas Pty Ltd
Website
https://vaxxas.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Vaxxas is a clinical-stage Australian biotechnology company developing the HD-MAP, a needle-free microarray patch platform for delivering vaccines to immune cells beneath the skin. It serves global pharmaceutical partners, government pandemic-preparedness agencies, and global-health organizations across programs in COVID-19, influenza, RSV, measles/rubella and typhoid.
Ownership category
akta.pro rank

Where Vaxxas is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Vaxxas business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Platform Licensing: Licensing the proprietary HD-MAP platform technology to global pharmaceutical companies for use with their vaccine candidates. Merck/MSD has exclusive rights for one vaccine candidate and options for two additional vaccines.
  2. Grant Funding and Government Contracts: Funding from government agencies (BARDA, EU HaDEA) and global charitable foundations (Gates Foundation, Wellcome, CEPI) to advance clinical programs and manufacturing capabilities.
  3. Direct Vaccine Product Commercialization: Commercializing proprietary and in-licensed vaccine candidates (COVID-19 HexaPro, RSV, pandemic influenza, typhoid, measles/rubella) through late-stage clinical trials to market entry.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Vaxxas product offering

Product offering

Core offering

Vaxxas develops and commercializes the proprietary HD-MAP (High-Density Microarray Patch) platform, a needle-free vaccine delivery technology consisting of a patch with thousands of vaccine-coated microprojections (~0.25mm) integrated with a single-use applicator that delivers vaccine to immune cells beneath the skin. The company applies this platform across multiple investigational vaccine programs including COVID-19, seasonal and pre-pandemic influenza, measles and rubella, RSV, and typhoid, while licensing the technology to global pharmaceutical partners such as Merck/MSD for use with their vaccine candidates.

Product overview

Vaxxas is commercializing the HD-MAP (High-Density Microarray Patch) as a universal needle-free vaccine delivery platform. The core HD-MAP technology consists of a small patch with thousands of microscopic vaccine-coated projections integrated into a single-use applicator device that delivers vaccine to immune cells just below the skin surface. Vaxxas applies this platform across multiple vaccine programs including COVID-19 (HexaPro), seasonal influenza (IIV4), pre-pandemic influenza (H7N9), measles and rubella, RSV, and typhoid, all delivered as investigational patches. The platform is designed to enable dose-sparing, thermostability (stable at up to 40°C), potential self-administration, and enhanced immunogenicity compared to needle-and-syringe delivery. The company is also advancing mRNA and DNA-based vaccine delivery via HD-MAP. Vaxxas operates under four commercial segments: pandemic response, HD-MAP licensing to pharmaceutical companies (including Merck/MSD), global health vaccine extension, and in-licensing vaccines for its own commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

  • HD-MAP (High-Density Microarray Patch) Platform
  • COVID-19 Vaccine Patch (HexaPro)
  • Seasonal Influenza Vaccine Patch (IIV4)
  • Pre-Pandemic Influenza Vaccine Patch (H7N9)
  • Measles and Rubella Vaccine Patch
  • RSV Vaccine Patch
  • Typhoid Vaccine Patch
  • mRNA Vaccine Delivery via HD-MAP
  • EU Next-Generation Influenza Vaccine Program

Quantifiable outcome

  • COVID-19 pandemic could have been reduced by 150 days with MAP technology deployment, potentially preventing 16.3 million cases and 200,000 deaths in US alone
  • +3 more outcomes

Companies that use Vaxxas

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Vaxxas technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Vaxxas partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, supporting and major.

  • SK biosciencecoreStrategic or Co-development Partner · 26 February 2026Part of global consortium awarded €12.9M Phase 1 tender by EU HaDEA for next-generation influenza vaccines. SK bioscience supplies vaccine antigens (SKYCellflu) and leads European collaboration. Consortium can access up to A$250M across phases.
  • IDT BiologikacoreStrategic or Co-development Partner · 26 February 2026Part of EU HaDEA consortium for influenza vaccine development. IDT Biologika (owned by SK bioscience) leads the consortium submission and provides CDMO capabilities. Over 100 years of vaccine development and manufacturing experience.
  • ObvioHealthsupportingTechnology or Integration · 28 October 2025Three-year partnership to support clinical trials using HD-MAP technology with ObvioGo digital trial platform. Decentralized trial capabilities to extend access.
  • CEPI (Coalition for Epidemic Preparedness Innovations)majorStrategic or Co-development Partner · 22 January 2025Partnering on US$4.8M/AU$7.2M program for needle-free thermostable mRNA vaccines. Joint development to eliminate frozen storage requirements for mRNA vaccines.
  • US National Institutes of Health (NIH)coreTechnology or Integration · 25 October 2024Licensed next-generation RSV vaccine candidate from NIH for worldwide development using HD-MAP platform.
  • University of SydneysupportingStrategic or Co-development Partner · 31 May 2022Collaborative study with University of Sydney Institute for Infectious Diseases assessing usability and acceptability of HD-MAP applicator in clinical settings. Published in Journal of Human Vaccines and Immunotherapeutics.
  • University of Texas at AustincoreTechnology or Integration · 23 March 2022Exclusively licensed HexaPro spike glycoprotein from UT Austin for use on needle-free vaccine patches. COVID-19 vaccine candidate completed Phase I trials.
  • World Health Organization (WHO)majorStrategic or Co-development Partner · 1 January 2021Previous collaboration on simulation of vaccine administration using HD-MAP with children in Low and Middle-Income Countries. WHO has acknowledged MAP technology in pandemic preparedness plans.
  • Harro HöfligersupportingTechnology or Integration · 28 May 2020Alliance to develop industrial-scale aseptic processing line for vaccine products based on HD-MAP technology. Supports manufacturing scale-up requirements.
  • Merck/MSDcoreStrategic or Co-development Partner · 1 January 2020Collaboration and license agreement where Merck has exclusive rights to utilize Vaxxas' HD-MAP platform for an undisclosed vaccine candidate from Merck's pipeline, with options for two additional vaccines. One of Vaxxas' foundational commercial partnerships.
  • University of QueenslandcoreTechnology or Integration · 1 January 2011Core technology (HD-MAP) initially developed at UQ's Australian Institute for Bioengineering and Nanotechnology. Commercialized as startup in 2011 through UniQuest.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Vaxxas competitors and assessment

Company assessment

Direct peers

  • Micron Biomedical: Micron Biomedical is the most direct competitor, developing dissolvable microneedle array patches for vaccines and therapeutics. Both target needle-free vaccine delivery with similar microarray patch architectures and are pursuing global health and pandemic preparedness use cases, often competing for the same Gates Foundation, CEPI, and government grant funding.
  • Vaxess Technologies: Vaxess is developing a sustained-release microarray patch for vaccine delivery using silk fibroin-based microneedles. Closely comparable technology platform and target use cases (influenza, pandemic preparedness, global health), positioned as a direct peer for both commercial licensing deals and non-dilutive funding opportunities.
  • PharmaJet: PharmaJet develops needle-free jet injector devices for vaccine administration (different mechanism but same needle-free vaccine delivery goal). Competes for the same global health and pandemic preparedness customers (WHO, Gates, CEPI) and targets similar market positioning around dose-sparing and cold-chain reduction.

Emerging players

  • Corium (transdermal drug delivery): Corium develops transdermal drug and vaccine delivery technologies including microarray and patch systems. Comparable technology overlap in the transdermal/microneedle delivery category, though Corium's primary focus has historically been CNS and small molecule drug delivery rather than vaccines.
  • Emergex Vaccines: Emergex is a clinical-stage biotech developing T-cell vaccines using microneedle patch delivery for infectious diseases including pandemic preparedness indications. Comparable stage, technology focus (microneedle delivery), and target indications (pandemic influenza, dengue) make it a relevant emerging peer.

Broad incumbents

  • Becton, Dickinson and Company (BD): BD is a global medical device incumbent with established injectable drug delivery and emerging microneedle programs, plus deep relationships with pharmaceutical partners and global health agencies. Represents both a potential partner and a formidable incumbent competitor as microarray patch commercialization scales.
  • Merck & Co. (MSD): Merck is Vaxxas' largest licensing partner for HD-MAP and the world's leading vaccine manufacturer (>$10B vaccine business). Both a critical partner and an emerging peer given Merck's option to license HD-MAP across multiple vaccine candidates plus potential internal patch development efforts.
  • CSL Seqirus: CSL Seqirus is a global influenza vaccine leader and an Australia-based peer comparable to Vaxxas on geography and target indication (seasonal and pandemic influenza). Relevant given Tom Lake (Vaxxas CBO) has deep CSL/Seqirus domain expertise and Vaxxas' H7N9 and seasonal flu programs target Seqirus's core market.
  • Sanofi Pasteur: Sanofi Pasteur is one of the world's largest vaccine manufacturers with deep pandemic preparedness capabilities and prior collaboration with Merck in vaccine manufacturing (Tom Lake's experience). Represents a plausible next licensing partner for HD-MAP and a strategic acquirer given platform synergies.
  • GSK Vaccines: GSK is a top-3 global vaccine manufacturer with strong portfolio overlap (influenza, measles/rubella, RSV, typhoid) where Vaxxas is developing HD-MAP programs. Comparable given Angus Forster (Vaxxas CTO/COO) and Tom Lake (Vaxxas CBO) both came from GSK. Plausible strategic partner or acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Vaxxas social profiles

Digital presence

Vaxxas compliance and trust

Trust signal

Compliance1 record

Vaxxas financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaxxas leadership team

Management profile

Number of profiles

Profiles10 records

Vaxxas funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaxxas M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxxas

What does Vaxxas do?

Vaxxas develops and commercializes the proprietary HD-MAP (High-Density Microarray Patch) platform, a needle-free vaccine delivery technology consisting of a patch with thousands of vaccine-coated microprojections (~0.25mm) integrated with a single-use applicator that delivers vaccine to immune cells beneath the skin. The company applies this platform across multiple investigational vaccine programs including COVID-19, seasonal and pre-pandemic influenza, measles and rubella, RSV, and typhoid, while licensing the technology to global pharmaceutical partners such as Merck/MSD for use with their vaccine candidates.

Is Vaxxas a public or private company?

Vaxxas is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vaxxas founded?

Vaxxas was founded in 2011. It employs 101 to 250 people.

Where is Vaxxas based?

Vaxxas is headquartered in Brisbane, Australia, in the Oceania region.

How does Vaxxas make money?

Three revenue lines are on record. Platform Licensing is the primary driver. The others are grant Funding and Government Contracts and direct Vaccine Product Commercialization.

Who are Vaxxas's main competitors?

Direct peers on record are Micron Biomedical, Vaxess Technologies and PharmaJet. Emerging players are Corium (transdermal drug delivery) and Emergex Vaccines. Broad incumbents are Becton, Dickinson and Company (BD), Merck & Co. (MSD), CSL Seqirus, Sanofi Pasteur and GSK Vaccines.

Does Vaxxas have an API?

No public API is recorded for Vaxxas.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireMicroneedle Patches Market to reach USD 7,695.8 Million by 2035 at 15.4% CAGRThe global microneedle patches market is projected to grow from $1,837.4 million in 2025 to $7,695.8 million by 2035, a 15.4% CAGR. Growth is driven by cold-chain cost elimination, regulatory clarity, and adherence economics, with North America holding 32.5% of 2025 revenue.PR NewswireMicroneedle Drug Delivery Systems Market to Reach USD 1.6 Billion by 2036 as Painless Vaccine Patches and Self-Administration Technologies Transform Global Drug DeliveryThe global microneedle drug delivery systems market is projected to grow from USD 0.8 billion in 2026 to USD 1.6 billion by 2036, expanding at a CAGR of 6.6%, driven by rising demand for painless, patient-centric drug delivery technologies. Solid microneedles dominate the product segment with 52.6% market share, while hospitals lead the end-use segment at 44.1%, supported by large-scale vaccination programs and chronic disease therapies. Key industry players including 3M Company, Becton Dickinson and Company, and Vaxxas are pursuing strategic partnerships, advanced vaccine patch development, and smart sensor integration to gain competitive advantage.openPR.comMicroneedle Patch Influenza Vaccine Delivery Market Forecast 2026-2036: Market to Reach USD 190.2 Million by 2036 at 23.00% CAGRFuture Market Insights released a market forecast report projecting the microneedle patch influenza vaccine delivery market to grow from USD 24.0 million in 2026 to USD 190.2 million by 2036, representing a compound annual growth rate of 23.00%. The market growth is driven by the global shift from cold-chain dependent liquid vaccines to thermostable, self-administered patch-based delivery systems, which addresses vulnerabilities in public health logistics and enables decentralized vaccination. The report identifies Vaxxas, Vaxess Technologies, Micron Biomedical, LTS Lohmann Therapie-Systeme AG, BioNet, Zipcode Bio, and PopVax as leading players in this emerging sector.PR NewswireSK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European UnionSK bioscience, IDT Biologika, and Vaxxas have been selected by the European Health and Digital Executive Agency (HaDEA) for Phase 1 of a next-generation influenza vaccine development initiative, using Vaxxas' needle-free high-density microarray patch (HD-MAP) technology to develop seasonal influenza vaccines for older adults and pandemic influenza vaccines. The contract is one of three EU-funded framework contracts worth up to €225 million total, with €12.9 million allocated to Phase 1 including clinical trials, and represents the first major global public funding secured following SK bioscience's acquisition of IDT. The consortium aims to enter the premium European seasonal influenza vaccine market and position itself for broader advanced market entry, with HD-MAP vaccines offering comparable immunogenicity at lower antigen doses with room-temperature stability.Idt-BiologikaIDT Biologika, SK bioscience and Vaxxas Selected for Next-Generation Influenza Vaccine Development Financed by the European UnionA consortium of IDT Biologika, SK bioscience, and Vaxxas has been selected by the EU's HaDEA agency for Phase 1 of a next-generation influenza vaccine development program, representing the first major public funding outcome following SK bioscience's acquisition of IDT Biologika. The contract is one of three EU-funded framework contracts worth up to €225 million total, with €12.9 million allocated for Phase 1 research and clinical trials, utilizing Vaxxas' needle-free high-density microarray patch technology. The consortium aims to develop seasonal influenza vaccines for older adults and pandemic influenza vaccines, targeting the premium European seasonal influenza vaccine market estimated at $459 million, with plans to expand to additional advanced markets including Korea and the United States.Lab + Life ScientistVaxxas appoints former Merck Global Vaccines President David Peacock as CEOVaxxas, a Brisbane-based biotechnology company developing high-density microarray patch (HD-MAP) vaccine delivery technology, has appointed David Peacock as CEO. Peacock brings over 25 years of global vaccine and pharmaceutical leadership experience, most recently serving as President of Merck Global Vaccines and President of MSD Asia Pacific. The appointment is aimed at advancing the commercialization of Vaxxas's HD-MAP technology, which the company states can improve vaccine manufacturing, distribution, and administration while addressing cold-chain and dose efficiency challenges.BioSpaceVaxxas Appoints Former Merck Global Vaccines President David Peacock as CEOVaxxas Pty Ltd has appointed David Peacock, former President of Merck Global Vaccines and MSD Asia Pacific, as Chief Executive Officer to lead commercialization of the company's high-density microarray patch (HD-MAP) vaccination technology. The appointment coincides with Vaxxas securing a manufacturing license from Australia's Therapeutic Goods Administration for its Brisbane biomedical facility, a regulatory milestone that de-risks the path to commercial supply. Peacock stated he aims to partner with pharmaceutical companies, research organisations, and governments to advance the HD-MAP technology toward global public-health and commercial impact.GlobeNewswireVaxxas Secures TGA Licence to Manufacture Therapeutic GoodsVaxxas Pty Ltd has been granted a manufacturing licence by the Therapeutic Goods Administration (TGA) to produce its proprietary HD-MAP vaccine delivery patches for clinical trials at its Brisbane facility. This regulatory approval allows the company to utilize its newly installed robotic lines for aseptic production, marking a key step toward commercializing the technology. The development aims to enhance global vaccine access by enabling self-administration and reducing cold-chain storage requirements.iTWireVaxxas Gets Green Light for Vaccine Patches and A Needle-Free FutureAustralian biotech company Vaxxas has received TGA approval to manufacture its needle-free high-density microarray vaccine patches (HD-MAPs) at its Brisbane facility, clearing a key regulatory hurdle ahead of late-stage clinical trials. The approval enables the company to leverage newly installed robotic manufacturing lines at its expanded 5,500m² facility and positions it competitively in the global vaccine delivery market. The milestone follows a $90 million funding round in 2025 and a three-year clinical trial partnership with ObvioHealth.BioSpaceVaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards MarketAustralian biotechnology company Vaxxas has appointed Mr Brent MacGregor, a veteran vaccine executive with over three decades of experience at CSL Seqirus, Novartis Vaccines, and Sanofi Pasteur, as an Independent Non-Executive Director to its Board to help advance its high-density microarray patch (HD-MAP) needle-free vaccine technology toward commercialization. Mr Michael Shleifer, Co-Founder and Managing Partner of SPRIM Global Investments, was also appointed Board Observer following Vaxxas' recent approximately $90 million financing round. Vaxxas has completed six Phase I clinical trials with over 750 participants, installed its first robotic manufacturing lines at a 5,500m2 facility in Brisbane, and partners with organizations including SK bioscience, CEPI, BARDA, and the Gates Foundation.